摘要
研究发现不同调脂方案的疗效存在明显的个体化差异 ,可能是多种参与脂质代谢相关蛋白基因突变和环境因素相互作用的结果。由于载脂蛋白对脂质代谢起到重要作用 ,因此载脂蛋白的基因突变已成为研究的热点之一。本文简述载脂蛋白A、B、C、E基因多态性对饮食和药物调脂疗效的影响。
出处
《中国动脉硬化杂志》
CAS
CSCD
2003年第6期586-588,共3页
Chinese Journal of Arteriosclerosis
参考文献39
-
1[1]Mata P, Lopez-Miranda J, Pocovi M, Alonso R, Lahoz C, Marin C, et al. Human apolipoprotein AI gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis, 1998, 137 (2): 367-376
-
2[2]Lopez-Miranda J, Ordovas JM,Espino A, Marin C, Salas J, Lopez-Segura F,et al. Influence of mutation in human apoliprotein A-I gene promoter on plasma LDL-cholesterol response to dietary fat. Lancet, 1994, 343 (7): 1 246-249
-
3[3]Mata P, Ordovas JM, Lopez-Miranda J, Lichtenstein AH, Clevidence B, Judd JT,et al. ApoA-IV phenotype affects diet induced plasma LDLcholesterol lowering. Arterioscler Thromb, 1994, 14(4): 884-891
-
4[4]Weinberg RB, Geissinger BW, Kasala K, Hockey KJ, Terry JG,Easter L,et al. Effect of apolipoprotein A-IV genotype and dietary fat on cholesterol absorption in humans. J Lipid Res, 2000, 41(12): 2 035-041
-
5[5]Clifton P, Kind K, Jones C, Noakes M. Response to dietary fat and cholesterol and genetic polymorphism. Clin Exp Pharmacol Physiol, 1997, 24 (1): A21-25
-
6[6]Carmena-Ramon RF, Ordovas JM, Ascaso JF, Real J, Priego MA, Carmena R. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia. Atherosclerosis, 1998, 139 (1): 107-113
-
7[7]Marin C, Lopez-Miranda J, Gomez P, PazE, Perez-Martinez P, Fuentes F, et al. Effects of the human apolipoprotein A-I promoter G-A mutation on postprandial lipoprotein metabolism. Am J Clin Nutr, 2002, 76(2): 319-325
-
8[8]Rantala M, Rantala TT, Savolainen MJ, Friedlander Y, Kesaniemi YA. Apolipoprotein B gene polymorphisms and serum lipids: meta-analysis of the role of genetic variation in responsiveness to diet. Am J Clin Nutr, 2000, 71(3): 713-724
-
9[9]Humphries SE, Talmud PJ, Cox C, Sutherland W, Mann J. Genetic factors affecting the consistency and magnitude of changes in plasma cholesterol in response to dietary challenge. QJM, 1996, 89 (9): 671-680
-
10[10]Lopez-Miranda J, Marin C, Castro P, Gomez P, Gonzalez-Amieva A, PazE, et al. The effect of apolipoprotein B xbaI polymorphism on plasma lipid response to dietary fat. Eur J Clin Invest, 2000, 30(8): 678-684
同被引文献17
-
1陈燕燕,李光伟,李春梅,黄晓红,鞠振宇,孙淑湘,蔡惠,惠汝太.G蛋白β_3亚单位C825T与高血压、胰岛素抵抗及肥胖的关联[J].中华医学杂志,2003,83(14):1229-1232. 被引量：25
-
2Beige J, Hohenbleicher H, Distler A, Sharma AM. G Protein beta 3 subunit C825T variant and ambulatory blood pressure in essential hypertension. Hypertension, 1999, 33 (4): 1 049-051.
-
3Brand E, Herrmann SM, Nicaud V, Ruidavets JB, Evans A, Arveiler D, et al. The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. Hypertension, 1999, 33 (5): 1 175-178.
-
4Siffert W, Forster P, Jochet KH, Mvere DA, Brinkmann B, Naber C, et al. Worldwide Ethnic distribution of the G protein β3 subunit C825T allele and its association with obesity in Caucasian, Chinese and Black African individuals. J Am Soc Nephrol, 1999, 10 (8): 1 921-930.
-
5Buchmayer H, Sunder-Plassmann G, Hirschl MM, Kletzmayr J, Woisetschlager C, Laggner AN, et al. G protein beta 3 subunit gene (GNB3) polymorphism 825C→T in patients with hypertensive crisis. Crit Care Med, 2000, 28 (9): 3 203-206.
-
6Larson N, Hutchinson R, Boerwinkle E. Lack of association of 3 functional gene variants with hypertension in African Americans. Hypertension, 2000, 35 (6): 1 297-300.
-
7Benjafield AV, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ. G protein beta 3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension, 1998, 32 (6): 1 094-097.
-
8Hegele RA, Harris SB, Hanley AJ, Cao H, Zinman B. G protein beta 3 subunit gene variant and blood pressure variation ni Canadian Oji-Cree. Hyperteion, 1998, 32 (4): 688-692.
-
9Kato N, Sugiyama T, Morita H, Kurihara H, Yamori Y, Yazaki Y. G protein beta 3 subunit variant and essential hypertension in Japanese. Hypertension, 1998, 32 (5): 935-938.
-
10Ishikawa K, Imai Y, Katsuya T, Ohkubo T, Tsuji I, Nagai K, et al. Human G protein beta 3 subunit variant is associated with serum potassium and total cholesterol levels but not with blood pressure. Am J ypertens, 2000, 13 (2): 140-145.
二级引证文献6
-
1李晓宇,郭冬平,蒋莉,白小明,何龙,范乐明,陈琪.家兔新基因Gnas的鉴定及其在高脂血症中的功能[J].中国动脉硬化杂志,2006,14(12):1025-1027. 被引量：1
-
2王晓苏,白怀,范平,刘瑞,刘宇,刘秉文.成都地区肥胖患者GNB3基因825C／T多态性研究[J].中华医学遗传学杂志,2008,25(6):670-674. 被引量：3
-
3王惠凌,李震中,陈宁,周岩,张瑞芳,王鸿超,白杰.原发性高血压患者GNB3基因多态性的研究[J].临床荟萃,2011,26(9):766-768. 被引量：2
-
4王惠凌,李震中,张军峰,王志尊,史福平.有高血压史的脑梗死患者G蛋白β3亚基基因C825T多态性研究[J].国际脑血管病杂志,2011,19(8):580-584.
-
5吴存造,杨亦荣,潘晓东,郭勇,倪晓洁,孙贤斌,夏鹏.他克莫司对肾移植受者血脂的影响及其与GNB3基因C825T多态性的相关性研究[J].中华器官移植杂志,2014,35(3):129-132. 被引量：8
-
6吴存造,廖毅,杨亦荣,郭勇,孙贤斌,陈必成,夏鹏.FK506对肝移植术后血脂影响及高脂血症和GNB3基因C825T多态性的关系[J].肝胆胰外科杂志,2014,26(3):207-210. 被引量：1
-
1刘兰芳.血脂异常治疗进展[J].中华临床医药杂志（北京）,2003,4(24):101-102.
-
2熊健,张惠萍.浅谈调脂治疗在冠心病防治中的重要性[J].中华临床医药杂志（北京）,2003,4(24):96-96.
-
3张栩,袁荣玺,沈立英.调脂治疗的几点新认识[J].锦州医学院学报,1998,19(4):47-49.
-
4汪家瑞,周北凡,陆宗良.血脂异常与调脂疗法[J].药物与人,2001,14(12):54-55.
-
5柴玉才.“调脂疗法”是防治心脑血管疾病最有效、最彻底的方法[J].健康博览,2006(9).
-
6李世芬.降压联合调脂治疗原发性高血压病临床分析[J].中国卫生产业,2013,10(8):115-115. 被引量：8
-
7调脂疗法未提出之前，如何治疗高血脂症？[J].长寿,2005(5).
-
8杨胜利,何秉贤.载脂蛋白基因多态性与冠心病[J].新疆医科大学学报,2000,23(1):88-90.
-
9马向华.载脂蛋白基因多态性与NIDDM[J].江苏医药,1994,20(9):496-497.
-
10王丹丹.85例调脂治疗对2型糖尿病眼底病变的临床疗效分析[J].中国医药指南,2015,13(6):131-132. 被引量：2
